The Conference on Cell & Gene Therapy for HIV Cure is supported by the following organizations:
We are currently accepting corporate sponsorship for the 2019 conference.
Please contact firstname.lastname@example.org for sponsorship inquires.
Guided by the belief that every life has equal value, the Bill & Melinda Gates Foundation works to help all people lead healthy,
productive lives. In developing countries, it focuses on improving people’s health and giving them the chance to lift themselves out of hunger
and extreme poverty. In the United States, it seeks to ensure that all people—especially those with the fewest resources—have access to the opportunities they need to succeed in school and life. Based in Seattle, Washington, the foundation is led by CEO Sue Desmond-Hellmann
and Co-chair William H. Gates Sr., under the direction of Bill and Melinda Gates and Warren Buffett.
Abbott Molecular is an emerging leader in molecular diagnostics and the analysis of DNA, RNA, and proteins at the molecular level. We are committed to exploring new clinical frontiers through the development and delivery of system and assay solutions that are designed to provide earlier disease diagnosis, selection of appropriate therapies and monitoring of disease recurrence. Our expanding portfolio brings multiples technologies that enable fast, accurate results. Our state of the art research and manufacturing facilities have hundreds of scientists who are dedicated to producing quality and reliable products.
amfAR, The Foundation for AIDS Research
amfAR, The Foundation for AIDS Research, is one of the world’s leading nonprofit organizations dedicated to the support of AIDS research, HIV prevention, treatment education, and advocacy. Since 1985, amfAR has invested nearly $550 million in its programs and has awarded more than 3,300 grants to research teams worldwide.
Today amfAR’s research focus is on the development of a cure for HIV. It is pursuing this goal through multi-year grants supporting both basic science and clinical studies, and a range of special initiatives. This includes the amfAR Research Consortium on HIV Eradication (ARCHE), a grant-making initiative that supports collaborative teams of scientists in the U.S. and around the world working on a range of HIV cure strategies.
In 2016, we established the amfAR Institute for HIV Cure Research with a five-year $20 million grant to the University of California, San Francisco. And IciStem is a consortium of European researchers created and funded by amfAR that is following a cohort of patients with cancer and HIV who have received, or soon will receive, a stem cell transplant. The cohort includes “the London patient” and “the Düsseldorf patient.”
For more information, visit www.amfar.org.
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. We strive to transform and simplify care for people with life-threatening illnesses around the world. Gilead's portfolio of products and pipeline of investigational drugs includes treatments for HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions.
Our portfolio of marketed products includes a number of category firsts, including complete treatment regimens for HIV infection available in a once-daily single pill and the first oral antiretroviral pill available to reduce the risk of acquiring HIV infection in certain high-risk adults.